<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02836990</url>
  </required_header>
  <id_info>
    <org_study_id>Prevena</org_study_id>
    <nct_id>NCT02836990</nct_id>
  </id_info>
  <brief_title>Prevena™ vs Dermabond in Groin Wound Infections in Vascular Surgery</brief_title>
  <official_title>Prevena™ Incision Management System Versus Dermabond in the Prevention of Groin Wound Infections in Patients Undergoing Vascular Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCI USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the clinical efficacy and cost effectiveness of Prevena Incision&#xD;
      Management System versus Dermabond in preventing groin wound infections in patients who&#xD;
      undergo vascular surgery requiring a groin wound. Half of the patients will receive Dermabond&#xD;
      and the other half will receive the Prevena Incision Management System for their groin&#xD;
      wounds.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dermabond and the Prevena Incision Management System are both FDA approved wound care&#xD;
      products. Prevena is a negative pressure system which holds the wound together and removes&#xD;
      exudate and debris from the site to prevent infection. Dermabond is a surgical glue which&#xD;
      holds the wound together to prevents infection. Prevena is more expensive to apply. However,&#xD;
      the hypothesis is that the Prevena System will decrease infection rates and therefore,&#xD;
      decrease the ultimate cost of the health care needed after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">September 2019</completion_date>
  <primary_completion_date type="Actual">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Healing of Groin Wounds Between Patients Treated With Prevena vs Dermabond</measure>
    <time_frame>30 days</time_frame>
    <description>The primary effectiveness endpoint is 30 day healing of the randomized groin incision, with any wound infection or failure to heal. Szilagyi wound infection grade quantified on an ordinal scale will be used to assess the healing (None, Grade I: Infection contained to the dermis, Grade II: Infection extending into the subcutaneous tissue but the arterial graft is not involved, Grade III: Infection of the arterial graft or native vessel underlying the incision).&#xD;
Healing is assessed by complete sealing of the incision with no residual separation or drainage. All of the incisions were primarily closed, so a healed incision would have no gaps between the skin edges. This is a visual inspection.&#xD;
Szilagi is an assessment of the grade of wound infection for those that did not heal. It is well recognized and published, and noted as above for patients with vascular exposure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost of Care</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of cost of treatment between the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Visiting Nurses Home Visits and Physician Office Visits to Assess/Treat Wound Infection</measure>
    <time_frame>30 days</time_frame>
    <description>Physician office visits for diagnosis of Infection or visiting nurse visits for diagnosis of infection ONLY were assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Wound Infection</condition>
  <arm_group>
    <arm_group_label>Prevena</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prevena Incision Management System for vascular surgical groin wounds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dermabond</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dermabond for vascular surgical groin wounds</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prevena Incision Management System</intervention_name>
    <description>A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections</description>
    <arm_group_label>Prevena</arm_group_label>
    <other_name>Prevena</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dermabond</intervention_name>
    <description>A surgical skin adhesive used to prevent surgical wound infections</description>
    <arm_group_label>Dermabond</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. In need of elective vascular procedure requiring ≥8 cm groin incision.&#xD;
&#xD;
          2. Able to provide consent&#xD;
&#xD;
          3. Able to care for wound or have support person to complete wound care&#xD;
&#xD;
          4. Willing to comply with follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Harris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of New York at Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaleida Health, Gates Vascular Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.woundsource.com/product/prevena-incision-management-system</url>
    <description>Prevena TM Incision Management System</description>
  </link>
  <reference>
    <citation>Ploeg AJ, Lardenoye JW, Peeters MP, Hamming JF, Breslau PJ. Wound complications at the groin after peripheral arterial surgery sparing the lymphatic tissue: a double-blind randomized clinical trial. Am J Surg. 2009 Jun;197(6):747-51. doi: 10.1016/j.amjsurg.2008.04.014. Epub 2008 Oct 17.</citation>
    <PMID>18929355</PMID>
  </reference>
  <reference>
    <citation>Lee ES, Santilli SM, Olson MM, Kuskowski MA, Lee JT. Wound infection after infrainguinal bypass operations: multivariate analysis of putative risk factors. Surg Infect (Larchmt). 2000 Winter;1(4):257-63.</citation>
    <PMID>12594881</PMID>
  </reference>
  <reference>
    <citation>Lawlor DK, Derose G, Harris KA, Lovell MB, Novick TV, Forbes TL. The role of platelet-rich plasma in inguinal wound healing in vascular surgery patients. Vasc Endovascular Surg. 2011 Apr;45(3):241-5. doi: 10.1177/1538574411399157.</citation>
    <PMID>21478245</PMID>
  </reference>
  <reference>
    <citation>Exton RJ, Galland RB. Major groin complications following the use of synthetic grafts. Eur J Vasc Endovasc Surg. 2007 Aug;34(2):188-90. Epub 2007 May 18.</citation>
    <PMID>17512763</PMID>
  </reference>
  <reference>
    <citation>Engin C, Posacioglu H, Ayik F, Apaydin AZ. Management of vascular infection in the groin. Tex Heart Inst J. 2005;32(4):529-34.</citation>
    <PMID>16429897</PMID>
  </reference>
  <reference>
    <citation>Bandyk DF. Vascular surgical site infection: risk factors and preventive measures. Semin Vasc Surg. 2008 Sep;21(3):119-23. doi: 10.1053/j.semvascsurg.2008.05.008. Review.</citation>
    <PMID>18774446</PMID>
  </reference>
  <reference>
    <citation>Swinnen J, Chao A, Tiwari A, Crozier J, Vicaretti M, Fletcher J. Vertical or transverse incisions for access to the femoral artery: a randomized control study. Ann Vasc Surg. 2010 Apr;24(3):336-41. doi: 10.1016/j.avsg.2009.07.020. Epub 2009 Dec 4.</citation>
    <PMID>19962270</PMID>
  </reference>
  <reference>
    <citation>Dosluoglu HH, Loghmanee C, Lall P, Cherr GS, Harris LM, Dryjski ML. Management of early (&lt;30 day) vascular groin infections using vacuum-assisted closure alone without muscle flap coverage in a consecutive patient series. J Vasc Surg. 2010 May;51(5):1160-6. doi: 10.1016/j.jvs.2009.11.053. Epub 2010 Mar 31.</citation>
    <PMID>20356703</PMID>
  </reference>
  <reference>
    <citation>Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999 Apr;20(4):250-78; quiz 279-80.</citation>
    <PMID>10219875</PMID>
  </reference>
  <reference>
    <citation>Easterlin B, Bromberg W, Linscott J. A Novel Technique of Vacuum-assisted Wound Closure That Functions as a Delayed Primary Closure. Wounds. 2007 Dec;19(12):331-3.</citation>
    <PMID>25942681</PMID>
  </reference>
  <reference>
    <citation>de Lissovoy G, Fraeman K, Hutchins V, Murphy D, Song D, Vaughn BB. Surgical site infection: incidence and impact on hospital utilization and treatment costs. Am J Infect Control. 2009 Jun;37(5):387-397. doi: 10.1016/j.ajic.2008.12.010. Epub 2009 Apr 23.</citation>
    <PMID>19398246</PMID>
  </reference>
  <reference>
    <citation>Weir G. The use of a surgical incision management system on vascular surgery incisions: a pilot study. Int Wound J. 2014 Jun;11 Suppl 1:10-2. doi: 10.1111/iwj.12261.</citation>
    <PMID>24851730</PMID>
  </reference>
  <reference>
    <citation>Matatov T, Reddy KN, Doucet LD, Zhao CX, Zhang WW. Experience with a new negative pressure incision management system in prevention of groin wound infection in vascular surgery patients. J Vasc Surg. 2013 Mar;57(3):791-5. doi: 10.1016/j.jvs.2012.09.037. Epub 2013 Jan 9.</citation>
    <PMID>23312938</PMID>
  </reference>
  <reference>
    <citation>Bruns TB, Worthington JM. Using tissue adhesive for wound repair: a practical guide to dermabond. Am Fam Physician. 2000 Mar 1;61(5):1383-8. Review.</citation>
    <PMID>10735344</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <results_first_submitted>February 25, 2020</results_first_submitted>
  <results_first_submitted_qc>December 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 28, 2020</results_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York at Buffalo</investigator_affiliation>
    <investigator_full_name>Linda Harris</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 17, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02836990/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02836990/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from UBMD Vascular Surgery Office and were consented at the time of surgery at Buffalo General Medical Center between 2016 and 2019.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Prevena</title>
          <description>Prevena Incision Management System for vascular surgical groin wounds&#xD;
Prevena Incision Management System: A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections</description>
        </group>
        <group group_id="P2">
          <title>Dermabond</title>
          <description>Dermabond for vascular surgical groin wounds&#xD;
Dermabond: A surgical skin adhesive used to prevent surgical wound infections</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Several patients randomized did not receive the randomized treatment based on physician decision, and were excluded from analysis as actual treatment rather than intent to treat was assessed.</population>
      <group_list>
        <group group_id="B1">
          <title>Prevena</title>
          <description>Prevena Incision Management System for vascular surgical groin wounds&#xD;
Prevena Incision Management System: A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections</description>
        </group>
        <group group_id="B2">
          <title>Dermabond</title>
          <description>Dermabond for vascular surgical groin wounds&#xD;
Dermabond: A surgical skin adhesive used to prevent surgical wound infections</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="10"/>
                    <measurement group_id="B2" value="68" spread="12"/>
                    <measurement group_id="B3" value="68" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Healing of Groin Wounds Between Patients Treated With Prevena vs Dermabond</title>
        <description>The primary effectiveness endpoint is 30 day healing of the randomized groin incision, with any wound infection or failure to heal. Szilagyi wound infection grade quantified on an ordinal scale will be used to assess the healing (None, Grade I: Infection contained to the dermis, Grade II: Infection extending into the subcutaneous tissue but the arterial graft is not involved, Grade III: Infection of the arterial graft or native vessel underlying the incision).&#xD;
Healing is assessed by complete sealing of the incision with no residual separation or drainage. All of the incisions were primarily closed, so a healed incision would have no gaps between the skin edges. This is a visual inspection.&#xD;
Szilagi is an assessment of the grade of wound infection for those that did not heal. It is well recognized and published, and noted as above for patients with vascular exposure.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevena</title>
            <description>Prevena Incision Management System for vascular surgical groin wounds&#xD;
Prevena Incision Management System: A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections</description>
          </group>
          <group group_id="O2">
            <title>Dermabond</title>
            <description>Dermabond for vascular surgical groin wounds&#xD;
Dermabond: A surgical skin adhesive used to prevent surgical wound infections</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Healing of Groin Wounds Between Patients Treated With Prevena vs Dermabond</title>
          <description>The primary effectiveness endpoint is 30 day healing of the randomized groin incision, with any wound infection or failure to heal. Szilagyi wound infection grade quantified on an ordinal scale will be used to assess the healing (None, Grade I: Infection contained to the dermis, Grade II: Infection extending into the subcutaneous tissue but the arterial graft is not involved, Grade III: Infection of the arterial graft or native vessel underlying the incision).&#xD;
Healing is assessed by complete sealing of the incision with no residual separation or drainage. All of the incisions were primarily closed, so a healed incision would have no gaps between the skin edges. This is a visual inspection.&#xD;
Szilagi is an assessment of the grade of wound infection for those that did not heal. It is well recognized and published, and noted as above for patients with vascular exposure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cost of Care</title>
        <description>Comparison of cost of treatment between the two arms</description>
        <time_frame>30 days</time_frame>
        <population>not analyzed as the primary outcome did not demonstrate improved outcomes, and the device being tested, wound vacuum, was more expensive. Had outcomes clinically been improved, financial assessment would have determined whether cost of infection outweighed cost of device.</population>
        <group_list>
          <group group_id="O1">
            <title>Preveena</title>
            <description>Outcome measures for cost were not calculated as initially planned as the primary outcome did not demonstrate any superiority with the Wound vacuum device, which is more expensive than the dermabond. Had there been improved clinical outcomes, financial benefit would have been assessed by comparing costs of infection vs device cost.&#xD;
As the primary outcome was not improved, this outcome was no longer necessary.</description>
          </group>
          <group group_id="O2">
            <title>Dermabond</title>
            <description>Assessment not performed financially as Dermabond is less expensive than Preveena, and preveena did not achieve clinical superiority invalidating the need for this analysis to determine whether Preveena was more cost effective for the system.</description>
          </group>
        </group_list>
        <measure>
          <title>Cost of Care</title>
          <description>Comparison of cost of treatment between the two arms</description>
          <population>not analyzed as the primary outcome did not demonstrate improved outcomes, and the device being tested, wound vacuum, was more expensive. Had outcomes clinically been improved, financial assessment would have determined whether cost of infection outweighed cost of device.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Visiting Nurses Home Visits and Physician Office Visits to Assess/Treat Wound Infection</title>
        <description>Physician office visits for diagnosis of Infection or visiting nurse visits for diagnosis of infection ONLY were assessed.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevena</title>
            <description>Prevena Incision Management System for vascular surgical groin wounds&#xD;
Prevena Incision Management System: A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections</description>
          </group>
          <group group_id="O2">
            <title>Dermabond</title>
            <description>Dermabond for vascular surgical groin wounds&#xD;
Dermabond: A surgical skin adhesive used to prevent surgical wound infections</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Visiting Nurses Home Visits and Physician Office Visits to Assess/Treat Wound Infection</title>
          <description>Physician office visits for diagnosis of Infection or visiting nurse visits for diagnosis of infection ONLY were assessed.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>40 days from time of surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prevena</title>
          <description>Prevena Incision Management System for vascular surgical groin wounds&#xD;
Prevena Incision Management System: A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections</description>
        </group>
        <group group_id="E2">
          <title>Dermabond</title>
          <description>Dermabond for vascular surgical groin wounds&#xD;
Dermabond: A surgical skin adhesive used to prevent surgical wound infections</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Reoperation for groin complication</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Linda Harris</name_or_title>
      <organization>University at Buffalo, SUNY</organization>
      <phone>7168594207</phone>
      <email>lmharris@buffalo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

